Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wangshi Baochi Pills (WBP) is a traditional Chinese medicine (TCM) compound herbal formulation classified as a national confidential formulary in China. It is widely used in clinical pediatrics to treat dyspepsia and functional constipation, particularly cases associated with food accumulation and internal heat. The formulation is characterized by its ability to evacuate stasis, resolve turbidity, clear heat, and invigorate the stomach. Mechanistic studies suggest that WBP inhibits oxidative stress by upregulating antioxidant enzymes, specifically Superoxide dismutase 1 (SOD1) and NAD(P)H quinone dehydrogenase 1 (NQO-1). Beyond its primary pediatric use, it has been investigated for treating gastrointestinal-type cold, hyperlipidemia, hypertension, and alcoholic liver disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Wangshi Baochi Pills.